“No effect on libido or mood”: the non -hormonal male pill crosses a historic course

It is an old sea serpent of biomedical research: the pill for men. For more than 60 years, men have been promised an equivalent of the women’s oral contraceptive, without ever managing to combine efficiency, reversibility and safety. This time, a team from the University of Minnesota may well have taken a decisive step with YCT -529, a non -hormonal molecule which has just succeeded in its first phase of tests in humans.

A pill, but without hormones or side effects

The results were made public at the end of July: YCT -529, administered to 16 volunteer men (all vasectomized, to exclude any risk of accidental fertilization), has not generated any major side effects. No drop in libido, no emotional instability, no measurable hormonal disturbance. And above all: excellent tolerance, even in the event of an empty stomach or after a meal.

This first phase, known as “1A”, only aimed to assess the safety of treatment and its pharmacological behavior. But the researchers are formal: YCT -529 checks all the boxes that no other molecule had gathered so far.

An unprecedented and reversible mode of action

Unlike hormonal approaches tested in the past (often based on testosterone suppression), YCT-529 acts by blocking a receiver called Rar-α, involved in the production of sperm. In rodents, almost complete contraception is observed within 4 weeks, with return to normal within two months of stopping treatment. In monkeys, same observation. And in humans? Response expected at the end of 2026.

The next step, in progress, is to test YCT -529 on several dozen non -vasectomized men, this time over several weeks, to assess its real impact on spermatogenesis. If the results are confirmed, marketing could occur from 2029 or 2030.

Want to save even more? Discover our selected promo codes for you.